30 Day Trial

Amplitude Surgical Reports FY1Q16 Revenue


Amplitude Surgical posted FY1Q16 (ended 9/30/15) revenue of €14MM (~US $15.1MM), +10.9% vs. the prior year. (France ~$9.3MM, +6.6%; International ~$5.8MM, +17.9%) Growth reflects constant currency.

At ~5% of overall group sales, Amplitude's Novastep subsidiary posted ~$0.65 in revenue. Of this, 37% were recorded in France and 63% abroad, primarily in the U.S.--Novastep's largest market.

The company notes that its Acor monoblock stem, beta launched in France in July 2015, is returning positive feedback. Also in July, the company registered its full range of hip and knee products in India and signed a commercial distribution agreement in Malaysia. 

Amplitude markets orthopaedic devices to treat lower limbs (hip, knee, extremities, foot/ankle) which it distributes in >30 countries, marketing via Novastep in France and the U.S. For FY2015 (ended 6/30/15), Amplitude recorded sales of €71.1MM (~$76.6MM).

Source: Amplitude Surgical